State Stem Cell Agency Standards Working Group Agenda 04-04-06

Apr 4, 2006
Main Location: 

California Institute for Regenerative Medicine
210 King Street, 3rd Floor
San Francisco, CA 94107

California State Stem Cell Agency

 

Regular Meeting 04-04-06

SCIENTIFIC & MEDICAL ACCOUNTABILITY STANDARDS WORKING GROUP
TO THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE (CIRM)

Organized Pursuant To The
CALIFORNIA STEM CELL RESEARCH AND CURES ACT

 
Date: April 4, 2006

Time: 12:00 PM - 1:00 PM (Estimated)

Location:

  • California Institute for Regenerative Medicine
    210 King Street, 3rd Floor
    San Francisco, CA 94107
 
 

OPEN SESSION

  1. Welcome
  2. Call to Order
  3. Roll Call
  4. CIRM Staff Progress Report
  5. Consideration of Regulations Governing the Use of Human Tissue in CIRM-Funded Research
  6. Discussion of Public Comments Received by the CIRM To Date on the MES Regulations (time permitting)
  7. Public comment

    [Members of the Public will be invited to provide testimony before or during consideration of each agenda item. Speakers are asked to limit their testimony to three (3) minutes.]

  8. Adjournment

 

THE ORDER OF BUSINESS MAY BE CHANGED WITHOUT NOTICE.
Notice is hereby given that the order of consideration of matters on this agenda may be changed without prior notice.

 


 

**NOTICE**

 

The California Institute for Regenerative Medicine and its Independent Citizen’s Oversight Committee, and any subcommittees thereof, comply with the Americans with Disabilities Act (ADA) by ensuring that the meeting facilities are accessible to persons with disabilities, and providing that this notice and information given to the Members of the Committee is available to the public in appropriate alternative formats when requested. If you need further assistance, including disability-related modifications or accommodations, you may contact Melissa King at the California Institute for Regenerative Medicine at (415) 396-9100 no later than the day prior to the meeting.

Questions or requests for additional information prior to the Scientific and Medical Research Funding Working Group meeting may be referred to Pat Beaupre Becker at the California Institute for Regenerative Medicine at pbecker@cirm.ca.gov or (415) 396-9105.

This meeting agenda is also available on the website for the California Institute for Regenerative Medicine at http://www.cirm.ca.gov.

 

Transcripts: 

© 2013 California Institute for Regenerative Medicine